Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Narrative) (Details)

v3.25.3
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Dec. 31, 2024
Jul. 15, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock warrant liabilities $ 2 $ 214  
Transfer between level 1 to 2 0    
Transfer between level 2 to 1 0    
Transfer between level 1 to 3 $ 0    
Risk-free interest rate | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Retained investment, deconsolidated subsidiary, measurement input 3.61    
Expected Volatility | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Retained investment, deconsolidated subsidiary, measurement input 80    
Discount for lack of marketability | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Retained investment, deconsolidated subsidiary, measurement input 31.6    
Avenue | Common Stock Warrant      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock warrant liabilities $ 2,000 $ 16,000  
Urica      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Shares received to maintain ownership Percentage 15.00%    
Urica | Asset Purchase, Royalty And Related Agreements With Crystalis      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Shares received to maintain ownership Percentage 15.00%   15.00%
Urica | Crystalys Therapeutics, Inc | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Estimated fair value $ 15,100